These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 22203761)

  • 1. Activation of peripheral-blood granulocytes is strongly correlated with patient outcome after immunotherapy with anti-GD2 monoclonal antibody and granulocyte-macrophage colony-stimulating factor.
    Cheung IY; Hsu K; Cheung NK
    J Clin Oncol; 2012 Feb; 30(4):426-32. PubMed ID: 22203761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission.
    Cheung NK; Cheung IY; Kushner BH; Ostrovnaya I; Chamberlain E; Kramer K; Modak S
    J Clin Oncol; 2012 Sep; 30(26):3264-70. PubMed ID: 22869886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Key role for myeloid cells: phase II results of anti-G(D2) antibody 3F8 plus granulocyte-macrophage colony-stimulating factor for chemoresistant osteomedullary neuroblastoma.
    Cheung NK; Cheung IY; Kramer K; Modak S; Kuk D; Pandit-Taskar N; Chamberlain E; Ostrovnaya I; Kushner BH
    Int J Cancer; 2014 Nov; 135(9):2199-205. PubMed ID: 24644014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of the anti-G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma.
    Kushner BH; Kramer K; Cheung NK
    J Clin Oncol; 2001 Nov; 19(22):4189-94. PubMed ID: 11709561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GM-CSF, G-CSF or no cytokine therapy with anti-GD2 immunotherapy for high-risk neuroblastoma.
    Mora J; Modak S; Kinsey J; Ragsdale CE; Lazarus HM
    Int J Cancer; 2024 Apr; 154(8):1340-1364. PubMed ID: 38108214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma.
    Kushner BH; Cheung NK
    Blood; 1989 May; 73(7):1936-41. PubMed ID: 2653466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancement of in vitro and in vivo anti-tumor activity of anti-GD2 monoclonal antibody 220-51 against human neuroblastoma by granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor.
    Fukuda M; Horibe K; Furukawa K
    Int J Mol Med; 1998 Oct; 2(4):471-5. PubMed ID: 9857237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor.
    Cheung NK; Sowers R; Vickers AJ; Cheung IY; Kushner BH; Gorlick R
    J Clin Oncol; 2006 Jun; 24(18):2885-90. PubMed ID: 16682723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytotoxicity of white blood cells activated by granulocyte-colony-stimulating factor, granulocyte/macrophage-colony-stimulating factor and macrophage-colony-stimulating factor against tumor cells in the presence of various monoclonal antibodies.
    Ragnhammar P; Frödin JE; Trotta PP; Mellstedt H
    Cancer Immunol Immunother; 1994 Oct; 39(4):254-62. PubMed ID: 7525059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment.
    Martinez Sanz P; van Rees DJ; van Zogchel LMJ; Klein B; Bouti P; Olsman H; Schornagel K; Kok I; Sunak A; Leeuwenburg K; Timmerman I; Dierselhuis MP; Kholosy WM; Molenaar JJ; van Bruggen R; van den Berg TK; Kuijpers TW; Matlung HL; Tytgat GAM; Franke K
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase Ib trial of granulocyte-macrophage colony-stimulating factor combined with murine monoclonal antibody R24 in patients with metastatic melanoma.
    Chachoua A; Oratz R; Liebes L; Alter RS; Felice A; Peace D; Vilcek J; Blum RH
    J Immunother Emphasis Tumor Immunol; 1994 Aug; 16(2):132-41. PubMed ID: 7804528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Granulocyte-macrophage colony-stimulating factor induces the expression of the CD11b surface adhesion molecule on human granulocytes in vivo.
    Socinski MA; Cannistra SA; Sullivan R; Elias A; Antman K; Schnipper L; Griffin JD
    Blood; 1988 Aug; 72(2):691-7. PubMed ID: 3042045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.
    Yu AL; Gilman AL; Ozkaynak MF; London WB; Kreissman SG; Chen HX; Smith M; Anderson B; Villablanca JG; Matthay KK; Shimada H; Grupp SA; Seeger R; Reynolds CP; Buxton A; Reisfeld RA; Gillies SD; Cohn SL; Maris JM; Sondel PM;
    N Engl J Med; 2010 Sep; 363(14):1324-34. PubMed ID: 20879881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early molecular response of marrow disease to biologic therapy is highly prognostic in neuroblastoma.
    Cheung IY; Lo Piccolo MS; Kushner BH; Cheung NK
    J Clin Oncol; 2003 Oct; 21(20):3853-8. PubMed ID: 14551304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Naxitamab combined with granulocyte-macrophage colony-stimulating factor as consolidation for high-risk neuroblastoma patients in complete remission.
    Mora J; Castañeda A; Gorostegui M; Santa-María V; Garraus M; Muñoz JP; Varo A; Perez-Jaume S; Mañe S
    Pediatr Blood Cancer; 2021 Oct; 68(10):e29121. PubMed ID: 34022112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin.
    Kushner BH; Ostrovnaya I; Cheung IY; Kuk D; Modak S; Kramer K; Roberts SS; Basu EM; Yataghene K; Cheung NK
    Oncotarget; 2016 Jan; 7(4):4155-66. PubMed ID: 26623730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group.
    Mody R; Yu AL; Naranjo A; Zhang FF; London WB; Shulkin BL; Parisi MT; Servaes SE; Diccianni MB; Hank JA; Felder M; Birstler J; Sondel PM; Asgharzadeh S; Glade-Bender J; Katzenstein H; Maris JM; Park JR; Bagatell R
    J Clin Oncol; 2020 Jul; 38(19):2160-2169. PubMed ID: 32343642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-G
    Kushner BH; Ostrovnaya I; Cheung IY; Kuk D; Kramer K; Modak S; Yataghene K; Cheung NK
    Oncoimmunology; 2015 Jul; 4(7):e1016704. PubMed ID: 26140243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of varying doses of granulocyte-macrophage colony-stimulating factor on pharmacokinetics and antibody-dependent cellular cytotoxicity.
    Liljefors M; Nilsson B; Mellstedt H; Frödin JE
    Cancer Immunol Immunother; 2008 Mar; 57(3):379-88. PubMed ID: 17676322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's Cancer Group Study.
    Ozkaynak MF; Sondel PM; Krailo MD; Gan J; Javorsky B; Reisfeld RA; Matthay KK; Reaman GH; Seeger RC
    J Clin Oncol; 2000 Dec; 18(24):4077-85. PubMed ID: 11118469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.